Race Oncology Ltd (ASX:RAC)’s Dr David Fuller speaks with Proactive’s Andrew Scott about the completion of the Phase 1b/2 Zantrene study taking place in AML at Chaim Sheba Israel. A milestone for RAC, this two-stage clinical trial is establishing the recommended dose to be used in the subsequent Phase 2 expansion (efficacy) stage. Effectively, Phase 1 was to identify treatment dosage with Phase 2 concentrating on efficacy.
Race Oncology Ltd advances Zantrene AML trials
